MannKind

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MannKind and other ETFs, options, and stocks.

About MNKD

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. 

CEO
Michael E. Castagna
CEOMichael E. Castagna
Employees
592
Employees592
Headquarters
Danbury, Connecticut
HeadquartersDanbury, Connecticut
Founded
1991
Founded1991
Employees
592
Employees592

MNKD Key Statistics

Market cap
1.21B
Market cap1.21B
Price-Earnings ratio
-50.51
Price-Earnings ratio-50.51
Dividend yield
Dividend yield
Average volume
5.20M
Average volume5.20M
High today
$4.02
High today$4.02
Low today
$3.83
Low today$3.83
Open price
$3.99
Open price$3.99
Volume
16.62M
Volume16.62M
52 Week high
$6.51
52 Week high$6.51
52 Week low
$2.23
52 Week low$2.23

Stock Snapshot

As of today, MannKind(MNKD) shares are valued at $3.91. The company's market cap stands at 1.21B, with a P/E ratio of -50.51.

On 2026-06-21, MannKind(MNKD) stock traded between a low of $3.83 and a high of $4.02. Shares are currently priced at $3.91, which is +2.1% above the low and -2.7% below the high.

MannKind(MNKD) shares are trading with a volume of 16.62M, against a daily average of 5.2M.

During the past year, MannKind(MNKD) stock moved between $2.23 at its lowest and $6.51 at its peak.

During the past year, MannKind(MNKD) stock moved between $2.23 at its lowest and $6.51 at its peak.

MNKD News

Simply Wall St 4d
Why MannKind Is Up 8.4% After New Afrezza Pediatric Approval And ADA Data Release

MannKind recently reported new clinical and real‑world data for its inhaled insulin Afrezza and FUROSCIX at the American Diabetes Association’s 2026 Scientific...

Why MannKind Is Up 8.4% After New Afrezza Pediatric Approval And ADA Data Release

Analyst ratings

88%

of 8 ratings
Buy
87.5%
Hold
12.5%
Sell
0%

People also own

Based on the portfolios of people who own MNKD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.